Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05890729 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
Enrollment reduced 66% 94 → 32 participants
See other at-risk trials from Xentria, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 8 more changesShow less
    • Enrollment reduced: 94 → 32 participants
    • Primary and study completion moved earlier from May 2029 to Oct 31, 2026
    • Enrollment closed, study ongoing
    • Trial arms changed: 5 → 4
    • Study sites: 34 to 33
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: 4 to 28
    • Study title expanded, about 7 words
  2. Primary and study completion dates: Apr 2026 to May 2029
    • Site details revised at 1 of 34 sites
    v34
  3. Site details revised at 5 of 34 sitesv33
  4. Study sites: 23 to 34v32
  5. Study sites: 22 to 23v31
Show 29 earlier versionsHide 29 earlier versions
  1. Study sites: 21 to 22v30
  2. Study sites: 20 to 21v29
  3. Study sites: 19 to 20v28
  4. Study sites: 18 to 19v27
  5. Study sites: 17 to 18v26
  6. Study sites: 16 to 17v25
  7. Study sites: 15 to 16v24
  8. Eligibility criteria shortened, about 70 wordsv23
  9. Study sites revised (15)v22
  10. Study sites: 14 to 15v21
  11. Site contacts updated at 2 of 14 sitesv20
  12. Study sites: 13 to 14v19
  13. Study sites: 12 to 13v18
  14. Eligibility criteria expanded, about 133 words
    • Secondary endpoints: 3 to 4
    v17
  15. Study sites: 11 to 12v16
  16. Study sites: 10 to 11v15
  17. Study sites: 9 to 10v14
  18. Study sites: 8 to 9v13
  19. Study sites: 6 to 8v12
  20. Study sites: 5 to 6
    • Start date changed from estimate of Oct 2023 to Nov 10, 2023
    v11
  21. Study sites: 4 to 5v10
  22. Study sites: 3 to 4v9
  23. Study sites: 2 to 3v8
  24. Study sites: 1 to 2v7
  25. Start date: Aug 2023 to Oct 2023v6
  26. Start date: Jul 2023 to Aug 2023
    • Site contact updated
    v5
  27. Trial status: Not Yet Recruiting to Recruitingv4
  28. Eligibility criteria expanded, about 6 wordsv3
  29. Eligibility criteria revised
    • Study title shortened, about 2 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Xentria, Inc.
6 trials monitored
See 3 trials at risk
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations
Trial Details
NCT Number NCT05890729
Lead Sponsor Xentria, Inc.
Conditions
(from sponsor)		 Pulmonary Sarcoidosis
Related terms Sarcoidosis, Pulmonary
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov